摘要
目的探讨氟马替尼二线治疗慢性髓系白血病慢性期(CML-CP)患者的疗效。方法回顾性分析2例CML-CP患者临床资料,并复习相关文献。结果1例患者伊马替尼400 mg/d治疗后出现全身皮疹,不耐受,并检测出集落刺激因子3受体(CSF3R)exon17(p.P733T)突变,转换氟马替尼治疗3个月后复查ISBCR-ABL1(P210)/ABL1达到主要分子学缓解(MMR);另1例患者伊马替尼治疗2年一直未达到MMR,转换氟马替尼治疗3个月后复查ISBCR-ABL1(P210)/ABL1达到MR4。结论对于伊马替尼不耐受或效果不佳的CML-CP患者,氟马替尼具有良好的疗效。
Objective To explore the efficacy of flumatinib in the second-line treatment of the patients with chronic myeloid leukemia chronic phase(CML-CP).Methods The clinical data in 2 cases of CML-CP were analyzed retrospectively,and the related literature was reviewed.Results One case developed the systemic rashes and intolerance after treatment with imatinib 400 mg/d,and CSF3R exon17(p.P733T)mutation was detected.After conversion of flumatinib treatment for 3 months,ISBCR-ABL1(P210)/ABL1 reached MMR in re-examination.The another case did not achieve MMR for 2-years imatinib treatment,and ISBCR-ABL1(P210)/ABL1 reached MR4 after 3-months flumatinib-conversion treatment.Conclusion For CML-CP patients with intolerant or poorly effective to imatinib,flumatinib has a good effect.
作者
蒋雅沁
王季石
肖仕珊
宋军
赵雪梅
李哲
朱红倩
JIANG Yaqin;WANG Jishi;XIAO Shishan;SONG Jun;ZHAO Xuemei;LI Zhe;ZHU Hongqian(Department of Hematology,Affiliated People′s Hospital,Guizhou Medical University,Guiyang,Guizhou 550002,China;Department of Hematology,Affiliated Hospital of Guizhou Medical University,Guiyang,Guizhou 550004,China)
出处
《重庆医学》
CAS
2021年第12期2030-2033,共4页
Chongqing medicine
基金
贵州省人民医院博士基金项目(GZSYBS[2019]03号)。
